To identify HLA-DR4 + donors, genomic DNA was extracted from leukocytes (Extract-N-Amp, sigma) and sent for SSP-PCR based HLA-typing (Children's Hospital Oakland Research Institute). All 26 subjects included in the study carried the HLA-DR4 MHC allele, had no known history of autoimmunity, and were CMV and HIV negative as determined by routine donor screening assays performed by the Stanford Blood Bank. The CMV testing was performed using Olympus PK CMV-PA Systems (Fujirebio Diagnostics) that detects CMV IgG and IgM antibodies. It has an overall sensitivity of 100% (95% CI 99.93-100%). The HIV detection was performed as part of the HIV/HBV/HCV Nucleic Acid Testing using COBAS TaqScreen MPX (Roche) that detects nucleic acids from HIV-1 group M, HIV-1 group O, HIV-2, HCV, and HBV. Overall sensitivity was estimated to be 100% (95% CI 99.76-100%). HSV typing was performed using Herpes Select HSV-1 and HV-2 Immunoblot (Focis Technologies). Assay sensitivity in sexually active adults relative to western blot was 99.3% (95% CI 95.9-100%) for HSV-1, and 97.3% (95% CI 90.7-99.7%) for HSV-2. Assay specificity was 95.1% (95% CI 89.0-98.4%) for HSV-1 and 98.1% (95% CI 94.7-99.6%) for HSV-2.
Influenza Vaccine Study
Two healthy individuals who have not received flu vaccine for at least 5 years were recruited to receive the seasonal influenza vaccination. A leukoreduction chamber was obtained prior to vaccination and 175 ml of whole blood was collected at the indicated times after vaccination. For tetramer analysis, approximately 20 -40 million pre-vaccination CD4 + T cells and 5-15 million post vaccination CD4 + T cells were used in each experiment, depending on availability. Hemagglutination inhibition antibody titer to the 2009 H1N1 virus (A/California/7/2009) was measured prior to vaccination and at each study visit, using methods previously described (Greenberg et al., 2009 ).
Antibodies, Dyes, and Tetramers
The antibodies used include: Purified anti-CD16 (clone 3G8), purified anti-CD32 (clone 3D3), PE.Cy5 labeled non-CD4 T cell markers against CD8a (clone HIT8a), CD19 (clone HIB19), CD11b (clone ICRF44), CD56 (clone MEM-188), FITC or AlexaFlour® 700 CD4 (clone RPA-T4), Pacific Blue CD45RO (clone UCHL1), Percp.Cy5.5 CCR7 (clone TG8/CCR7), and FITC IFNγ (clone 4S.B3). Dead cell exclusion was performed using Agua live-dead dye (Invitrogen). APC, PE, and PE-Cy7 conjugated streptavidin were obtained from eBiosciences. TCR V usage was assessed using the IOTest Beta Mark TCR Vbeta Repertoire Kit (Beckman Coulter, USA). The HLA-DR4 monomers with tethered thrombin cleavable CLIP peptide were purified by antibody affinity chromatography from the culture supernatant of a stable HLA-DR4 transfectant cell line (gift from Dr. Kai Wucherpfennig). The subsequent protein biotinylation, peptide exchange, and tetramerization were performed according to Day et al. (Day et al., 2003) . The peptide panel include: influenza hemagglutinin antigen -HA 306-318 GGPKYVKQNTLKLAT, influenza PB1 antigen -PB1 404-418 SPGMMMGMFNMLSTV, influenza PA antigen -PA 281-295 RSKFLLMDALKLSIE, HIV gag p24 antigen -HIV 164-183 AFSPEVIPMFSALSEGATPQ, Tetanus toxinTetanus 506-525 GAGSLQPLALEGSLQKRG, HSV VP16 antigen -VP16 472-484 DFEFEQMFTDAMG, CMV pp65 antigen -CMV1 201-220 AHELVCSMENTRATKMQVIG, CMV pp65 antigen -CMV2 231-250 FCEDVPSGKLFMHVTLGSDV, citrullinated Fibrinogen A antigen -Fib 171-185 VDIDIKI(CIT)SC(CIT)GSCS (with Arg to citrulline (cit) substitutions), preproinsulin -PPins 73-90 GAGSLQPLALEGSLQKRG, and gp100 44-59 WNRQLYPEWTEAQRLD.
Calculation of T Cell Frequency and Assay Sensitivity
The frequency of tetramer tagged cells was calculated based on the total number of tetramer positive cells divided by the starting cell number, obtained by back calculation of absolute cell count in 1/10 th of the initial staining reaction and the eluted fraction as determined by TruCOUNT (BD Biosciences). The sensitivity of the tetramer assay was determined by comparing the expected versus the actual numbers of PB1-specific cells recovered from 50-fold and 100-fold dilutions of DR4 + samples. The total number of PB1-specific cells detected was adjusted for nonspecific cell loss by multiplying the percentage of PB1 tetramer tagged cells to the absolute count of lymphocytes in the eluted fraction. The expected number of PB1-specific cells in the diluted samples were calculated by dividing the number of PB1 tetramer tagged cells from DR4 + donor by the dilution factor.
Single Cell Cloning
To generate antigen-specific clones, cells tagged by tetramers were single cell sorted using BD FACSAria into 96 well plates containing autologous irradiated feeder cells and PHA (1:100, sigma). IL2 (50U/ml) was added on day 4 and every 3 days thereafter (adapted from (Yssel and Spits, 2002) ). Proliferating clones were validated to be antigen-specific by re-staining with the same tetramer on day 14 -21.
Cell Stimulation and Proliferation Analysis
CD4 + lymphocytes isolated from blood were stimulated with PMA (150ng/ml) and ionomycin (1mM) for 3 hours in the presence of protein transport inhibitor (BD GolgiPlug and BD GolgiStop, adapted from a standard protocol (Foster et al., 2007) ), followed by tetramer enrichment, cell fixation and permeabilization (BD cytofix/cytoperm). T cell clones were stimulated by recombinant gp100 protein (4ug/ml, abcam), p24 protein (20ug/ml, abcam), or peptides (10ug/ml) in co-culture with plate bound HLA matched PBMC and protein transport inhibitors for 10 -12 hours. Intracellular cytokine staining with anti-IFNγ and IL2 antibody was carried out according to manufacturer protocol. Cell proliferation was performed by labeling cells with 5uM CFSE (Invitrogen) for 5 minutes at room temperature and co-culture for 4-5 days with peripheral monocyte derived dendritic cells generated according to McCurley et al. (McCurley and Mellman, 2010) .
Real-Time PCR and Gene Expression Analysis
HIV tetramer labeled and tetramer negative cells were sorted individually according CD45RO expression into 96-well plates containing 5 ul Reaction Mix from CellDirect One-Step qRT-PCR kit Invitrogen) and 0.1ul SUPERase-In (Ambion) per well. Reverse transcription and preamplification was performed to manufacturer's instruction (CellDirect, Invitrogen) with TagMan® Gene Expression Assay (Applied Biosystems). High-throughput real time PCR was performed on preamplified cDNA samples and analyzed on 48.48 or 96.96 dynamic arrays (Fluidgm). Data was processed by converting the expression to binary values (expressing versus not expressing) based on having a quality score > 0.65 and C T >= 30. All cells not expressing detectable level of B2M were excluded from further analysis and a univariate filter was applied to eliminate the lowest 60% of expressing genes based on overall variance. This filter removed non-and low expressing genes, which maximized the number of discoveries while controlling for type I error.
Single Cell TCR Sequencing
TCR sequences from single cells were obtained by a series of three nested PCR reactions. For the first reaction, reverse transcription and preamplification were performed with a CellsDirect One-Step qRT-PCR kit according to the manufacturer's instructions (CellsDirect, Invitrogen) using multiplex PCR with multiple V region primers and a C region primer. When necessary, base degeneracy was incorporated into the primers to account for TCR polymorphism and ensure amplification of all known TCRV and C regions identified in the IMGT database (http://www.imgt.org/). Next, an aliquot of the first reaction was used as a template for second PCR reaction using a set of multiple internally nested TCRV region primers and an internally nested C region primer with HotStarTaq DNA polymerase kit (Qiagen). The second set of TCRV region primers also incorporated base degeneracy when needed and also contained a common 23 base sequence at the 5' end to enable further amplification with a common 23 base primer. The third and final PCR reaction was performed on an aliquot of the second reaction using a primer containing the common 23 base sequence (incorporated into the second set of V primers) and a third internally nested C primer using Hotstar HiFidelity DNA polymerase kit (Qiagen). Amplified PCR products were treated with ExoSAP-IT (Affymetrix) and sequenced by Elim Biopharm using primers from the final PCR reaction. TCR junctional region analysis was performed using IMGT/V-Quest (http://www.imgt.org/IMGT_vquest). Primer sequences are listed in the supplemental table. 
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